Influence of an alkalizing supplement on markers of endurance performance using a double-blind placebo-controlled design

Table 7 Summary measures for eight (L1-L8) fingertip blood lactate analyses (mmol/L) from tests of upper body power

	Constant-Power Test		UBP10 Tests			UBP60 Test
Group	†L1	L2	Trial #1 L3	Trial #2 L4	Trial #3 L5	L6	L7	L8
Placebo Pre-Testing Post-Testing	5.3 ± 0.6 4.9 ± 0.6	5.0 ± 0.6 5.0 ± 0.7	5.1 ± 0.6 4.9 ± 0.6	5.6 ± 0.5 5.6 ± 0.5	6.4 ± 0.6 6.6 ± 0.5	9.2 ± 0.5 9.4 ± 0.5	9.8 ± 0.6 10.3 ± 0.6	9.7 ± 0.6 ‡10.3 ± 0.6
Treatment Pre-Testing Post-Testing	7.0 ± 0.6 ‡5.5 ± 0.6	5.8 ± 0.8 5.7 ± 0.7	6.1 ± 0.7 5.6 ± 0.7	6.6 ± 0.6 6.3 ± 0.6	7.2 ± 0.6 7.2 ± 0.7	9.8 ± 0.8 9.4 ± 0.7	10.9 ± 0.7 ‡9.8 ± 0.7	10.4 ± 0.7 ‡9.4 ± 0.6

NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test. Sample sizes remained at 12 subjects per group for both pre- and post-testing
†The eight blood lactate samples (L1-L8) are labeled the same as those shown within Figure 1
‡Mean post-testing blood lactate value differed significantly (P < 0.05) from corresponding pre-testing value within the same test group

ISSN: 1550-2783